View Older Stories View More Recent Stories

Mar 11, 2025 07:02AM Guardant Health (GH) Receives ADLT Status From CMS for Shield Blood Test
Mar 11, 2025 07:00AM Guardant Health Receives ADLT Status From CMS for Shield Blood Test
Mar 5, 2025 08:05AM Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities
Feb 28, 2025 05:05PM Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 27, 2025 08:05AM New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
Feb 20, 2025 04:05PM Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
Feb 10, 2025 07:00AM Guardant Health to Participate in Upcoming Investor Conferences
Jan 30, 2025 04:05PM Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Jan 30, 2025 08:05AM Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
Jan 23, 2025 08:05AM Guardant Health (GH) to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools
Jan 23, 2025 08:05AM Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
Jan 21, 2025 08:05AM Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
Jan 16, 2025 08:10AM Guardant Health (GH) and ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
Jan 16, 2025 08:05AM Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
Jan 13, 2025 07:00AM Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
Jan 7, 2025 08:03AM Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
Jan 2, 2025 04:05PM Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Dec 20, 2024 08:05AM Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
Dec 19, 2024 06:00AM COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
Dec 18, 2024 08:06AM Guardant Health (GH) Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
Dec 18, 2024 08:05AM Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
Dec 9, 2024 08:05AM Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer
Nov 25, 2024 05:09PM Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
Nov 13, 2024 05:05PM Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2024 04:05PM Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Nov 1, 2024 07:00AM Guardant Health to Participate in Upcoming Investor Conferences
Oct 30, 2024 09:30AM Guardant Health Named to TIME’s List of the Best Inventions of 2024
Oct 28, 2024 08:05AM Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
Oct 24, 2024 05:06PM Guardant Health (GH) Appoints Roberto A. Mignone to its Board
Oct 24, 2024 05:05PM Roberto A. Mignone Joins Guardant Health Board of Directors
Oct 15, 2024 04:05PM Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
Sep 18, 2024 08:05AM GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
Sep 13, 2024 02:00AM Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
Sep 10, 2024 08:00AM Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
Aug 27, 2024 04:05PM Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 22, 2024 05:00PM Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
Aug 8, 2024 04:05PM Guardant Health to Participate in Upcoming Investor Conferences
Aug 7, 2024 04:05PM Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Aug 7, 2024 08:05AM Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
Aug 1, 2024 08:33AM Guardant Health's (GH) FDA-approved Shield Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
Aug 1, 2024 08:30AM Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
Aug 1, 2024 08:00AM Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
Jul 29, 2024 07:34AM Guardant Health's (GH) Shield Blood Test Approved by FDA as Primary Screening Option, Clearing Path for Medicare Reimbursement
Jul 29, 2024 06:30AM Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
Jul 24, 2024 04:05PM Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
Jul 23, 2024 08:17AM Guardant Health (GH) Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360 Test
Jul 23, 2024 08:05AM Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
Jul 18, 2024 05:01PM Guardant Health (GH) Appoints Manuel Hidalgo Medina to its Board
Jul 18, 2024 05:00PM Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
Jun 4, 2024 08:05AM Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
View More Recent Stories View Older Stories